United States securities and exchange commission logo

                             September 17, 2020

       Randall C. Schatzman
       Chief Executive Officer
       Bolt Biotherapeutics, Inc.
       900 Chesapeake Drive
       Redwood City, CA 94063

                                                        Re: Bolt
Biotherapeutics, Inc.
                                                            Amendment No. 1 to
                                                            Draft Registration
Statement on Form S-1
                                                            Submitted September
11, 2020
                                                            CIK No. 0001641281

       Dear Dr. Schatzman:

             We have reviewed your amended draft registration statement and
have the following
       comments. In some of our comments, we may ask you to provide us with
information so we
       may better understand your disclosure.

              Please respond to this letter by providing the requested
information and either submitting
       an amended draft registration statement or publicly filing your
registration statement on
       EDGAR. If you do not believe our comments apply to your facts and
circumstances or do not
       believe an amendment is appropriate, please tell us why in your

             After reviewing the information you provide in response to these
comments and your
       amended draft registration statement or filed registration statement, we
may have additional

       Amendment No. 1 to Draft Registration Statement on Form S-1

       Our Pipeline, page 4

   1.                                                   We note your response
to our prior comment 3 and your explanation regarding the term
Please delete the "Registrational" column and revise the pipeline chart
                                                        to include individual
columns for each of the three phases of clinical development.
 Randall C. Schatzman
FirstName  LastNameRandall C. Schatzman
Bolt Biotherapeutics, Inc.
Comapany 17,
September  NameBolt
               2020 Biotherapeutics, Inc.
Page 2     17, 2020 Page 2
FirstName LastName
       You may contact Kristin Lochhead at 202-551-3664 or Daniel Gordon at
202-551-3486 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Donald Field at 202-551-3680 or Sonia Bednarowski at 202-551-3666 with
any other


                                                         Division of
Corporation Finance
                                                         Office of Life